ACADIA Pharmaceuticals (MEX:ACAD) Cyclically Adjusted Book per Share: MXN85.75 (As of Mar. 2026)


MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
73 GF Score
Price MXN362.00
GF Value MXN357.71
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Cyclically Adjusted Book per Share?

ACADIA Pharmaceuticals MEX:ACAD 73 Cyclically Adjusted Book per Share is MXN85.75 as of Mar. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN357.71 (Fairly Valued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

ACADIA Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was MXN131.548. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN85.75 for the trailing ten years ended in Mar. 2026.

During the past 12 months, ACADIA Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 10.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 3.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 7.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of ACADIA Pharmaceuticals was 17.20% per year. The lowest was 3.40% per year. And the median was 8.70% per year.

As of today (2026-06-29), ACADIA Pharmaceuticals's current stock price is MXN362.00. ACADIA Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was MXN85.75. ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 4.22.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of ACADIA Pharmaceuticals was 22.64. The lowest was 3.76. And the median was 7.66.


ACADIA Pharmaceuticals  (MEX:ACAD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=362.00/85.75
=4.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of ACADIA Pharmaceuticals was 22.64. The lowest was 3.76. And the median was 7.66.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


ACADIA Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


ACADIA Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Cyclically Adjusted Book per Share Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.52 108.06 61.94 105.68 69.29

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118.90 93.21 83.30 69.29 85.75

MEX:ACAD vs VKTX, EWTX, DNLI: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


MEX:ACAD
73GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ACADIA Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=131.548/330.2130*330.2130
=131.548

Current CPI (Mar. 2026) = 330.2130.

ACADIA Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 66.503 241.018 91.114
201609 92.291 241.428 126.231
201612 88.064 241.432 120.447
201703 70.620 243.801 95.650
201706 61.339 244.955 82.688
201709 55.801 246.819 74.655
201712 52.928 246.524 70.896
201803 44.279 249.554 58.591
201806 41.613 251.989 54.531
201809 33.429 252.439 43.728
201812 65.391 251.233 85.948
201903 56.306 254.202 73.143
201906 51.716 256.143 66.671
201909 88.629 256.759 113.984
201912 84.918 256.974 109.120
202003 96.299 258.115 123.198
202006 97.239 257.797 124.554
202009 91.063 260.280 115.530
202012 78.130 260.474 99.048
202103 74.224 264.877 92.532
202106 70.000 271.696 85.076
202109 72.547 274.310 87.332
202112 68.913 278.802 81.621
202203 54.878 287.504 63.030
202206 54.054 296.311 60.239
202209 52.898 296.808 58.852
202212 48.169 296.797 53.592
202303 41.544 301.836 45.450
202306 41.538 305.109 44.956
202309 38.475 307.789 41.278
202312 44.511 306.746 47.916
202403 46.686 312.332 49.359
202406 57.075 314.175 59.989
202409 68.318 315.301 71.549
202412 91.674 315.605 95.917
202503 93.680 319.799 96.731
202506 91.839 322.561 94.018
202509 99.480 324.800 101.138
202512 129.764 324.054 132.230
202603 131.548 330.213 131.548

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN85.75 mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Cyclically Adjusted Book per Share of MXN85.75 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Cyclically Adjusted Book per Share too high?
ACADIA Pharmaceuticals' current Cyclically Adjusted Book per Share is MXN85.75. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Cyclically Adjusted Book per Share compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Cyclically Adjusted Book per Share of MXN85.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Cyclically Adjusted Book per Share is MXN85.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN357.71, compared to a current price of MXN362.00 — trading 1.2% above its estimated fair value. The current Cyclically Adjusted Book per Share is MXN85.75. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Cyclically Adjusted Book per Share is MXN85.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN362.00 is trading 1.2% above its estimated GF Value™ of MXN357.71. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • Cyclically Adjusted Book per Share: MXN85.75
  • GF Value™: MXN357.71 vs. price of MXN362.00 (1.2% above fair value)
  • GF Score™: 73/100 with 9 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score

Get the complete analysis for MEX:ACAD

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN362.00
Price
MXN357.71
GF Value